

1 **Seroprevalence of SARS CoV-2 antibodies in healthcare workers and**
2 **administration employees: a prospective surveillance study at a 1,400-**
3 **bed university hospital in Germany**

4

5 Christina Bahrs,^{1,2#} Aurelia Kimmig,^{1#} Sebastian Weis,^{1,3} Juliane Ankert,¹ Stefan Hagel,¹ Jens
6 Maschmann,⁴ Andreas Stallmach,⁵ Andrea Steiner,⁶ Michael Bauer,³ Wilhelm Behringer,⁷
7 Michael Baier,⁸ Miriam Kesselmeier,⁹ Cora Richert,¹⁰ Florian Zepf,¹¹ Martin Walter,¹² André
8 Scherag,⁹ Michael Kiehntopf,¹⁰ Bettina Löffler,⁸ Mathias W. Pletz¹

9

both authors contributed equally

10

11

12 ¹ Institute for Infectious Diseases and Infection Control, Jena University Hospital/Friedrich-
13 Schiller-University, Jena, Germany

14 ² Department of Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical
15 University of Vienna, Vienna, Austria

16 ³ Department of Anesthesiology and Intensive Care Therapy, Jena University
17 Hospital/Friedrich-Schiller-University, Jena, Germany

18 ⁴ Medical Executive Board, Jena University Hospital, Germany

19 ⁵ Department of Internal Medicine IV (Gastroenterology, Hepatology and Infectious Diseases),
20 Jena University Hospital/Friedrich-Schiller-University, Jena, Germany

21 ⁶ Department for Occupational Health, Jena University Hospital/Friedrich-Schiller-University,
22 Jena, Germany

23 ⁷ Department of Emergency Medicine, Jena University Hospital/Friedrich-Schiller-University,
24 Jena, Germany

25 ⁸ Institute of Medical Microbiology, Jena University Hospital/Friedrich-Schiller-University,
26 Jena, Germany

27 ⁹ Institute of Medical Statistics, Computer and Data Sciences, Jena University
28 Hospital/Friedrich-Schiller-University, Jena, Germany

29 ¹⁰ Department of Clinical Chemistry and Laboratory Medicine, Jena University
30 Hospital/Friedrich-Schiller-University, Jena, Germany

31 ¹¹ Department of Child and Adolescent Psychiatry, Psychosomatic Medicine and
32 Psychotherapy, Jena University Hospital/Friedrich-Schiller-University, Jena, Germany

33 ¹² Department of Psychiatry and Psychotherapy, Jena University Hospital/Friedrich-Schiller-
34 University, Jena, Germany

35

36

37

38

39

40

41 **Corresponding author:**

42 Mathias W. Pletz, MD, Institute of Infectious Diseases and Infection Control, Jena University

43 Hospital/Friedrich-Schiller-University Am Klinikum 1, 07747 Jena, Germany. E-mail:

44 mathias.pletz@med.uni-jena.de Phone: +49-3641-932-4650, Fax: +49 3641 932 4652.

45

46 **Running title:** SARS-CoV-2 seroprevalence

47 **Keywords:** SARS-CoV-2, antibody response, healthcare workers, universal masking.

48 **Abstract**

49 **Background:** Healthcare workers (HCWs) are at particular risk to acquire SARS-CoV-2
50 infections.

51 **Aim:** The objectives of this study were to compare SARS-CoV-2 IgG seroprevalence and
52 compliance to wear personal protective equipment (PPE) between HCWs working within
53 (high-risk) or outside (intermediate-risk) units treating suspected or confirmed COVID-19
54 patients. In addition, administration staff (low-risk) was included.

55 **Materials:** Co-HCW is a prospective cohort study among employees at the Jena University
56 Hospital, Germany. Since 16th March 2020, 50 SARS-CoV-2 inpatients and 73 outpatients
57 were treated in our hospital. Mandatory masking was implemented on 20th March 2020. We
58 here evaluated seroprevalence using two IgG detecting immunoassays, assessed COVID-19
59 exposure, clinical symptoms and compliance to wear PPE.

60 **Findings:** Between 19th May and 19th June 2020 we analysed 660 employees [out of 3,228;
61 20.4%]. Eighteen participants (2.7%) had SARS-CoV-2 antibodies in at least one
62 immunoassay. Among them, 13 (72.2%) were not aware of direct COVID-19 exposure and 9
63 (50.0%) did not report any clinical symptoms. We observed no evidence for an association
64 between seroprevalence and risk area (high-risk: 2 of 137 HCWs (1.5%), intermediate-risk:
65 10 of 343 HCWs (2.9%), low-risk: 6 of 180 administration employees (3.3%); $p=0.574$).
66 Reported compliance to wear PPE differed ($p<0.001$) between working in high-risk (98.3%)
67 and in intermediate-risk areas (69.8%).

68 **Conclusion:** No evidence for higher seroprevalence against SARS-CoV-2 in HCWs working
69 in high-risk COVID-19 areas could be observed, probably due to high compliance to wear
70 PPE. Compared to administration employees, we observed no additional risk to acquire
71 SARS-CoV-2 infections by patient care.

72 **Introduction**

73 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel beta coronavirus
74 that was first identified in December 2019 in Wuhan, China [1, 2]. As of the beginning of 2020
75 the outbreak progressed and has been characterized as a pandemic in March 2020 [3, 4].
76 The clinical presentation of the disease caused by SARS-CoV-2, corona virus disease 2019
77 (COVID-19) [4], varies significantly and ranges from asymptomatic and mild to critical courses
78 [5-7]. As asymptomatic or pre-symptomatic patients can spread the virus [8-11], it is
79 challenging to timely identify and isolate respective cases. Due to the pandemic the disease
80 and health care burden remains high in many parts of the world
81 (<https://www.ecdc.europa.eu/en/geographical-distribution-2019-ncov-cases>). In Summer
82 2020, there were more than 1.3 Mio healthcare workers (HCWs) who have been tested
83 positive for SARS-CoV-2 worldwide [12].

84 SARS-CoV-2 is highly transmissible from human to human mainly via inhalation of infectious
85 respiratory droplets but also via close personal contact (shaking hands) and via touching
86 contaminated surfaces [2, 13]. As a consequence, nosocomial transmission of insufficiently
87 protected HCWs can occur during aerosol generating procedures [13-14], in the regular
88 patient contact particularly when exposed to patients with a delayed diagnosis of COVID-19
89 and also in close contact with asymptomatic but virus carrying colleagues [15-19]. Hence, it is
90 of great importance to implement infection prevention programs and provide HCWs with
91 sufficient personal protective equipment (PPE) in order to reduce nosocomial transmissions
92 [20]. Further reason for HCWs to be tested positive for COVID-19 is community transmission
93 in particular due to local outbreaks [21], and infectious returning travelers [2]. On 11th March
94 2020, the first COVID-19 cases were detected in the city of Jena, Germany. Only five days
95 later, a HCW returning from skiing in Austria caused the first nosocomial outbreak at the Jena
96 University Hospital (JUH) that involved further 31 newly confirmed SARS CoV-2 infections
97 until 19th March.

98 The primary objective of this study was to investigate the spread of SARS-CoV-2 infection by
99 testing for SARS CoV-2 IgG antibodies among employees of JUH with and without patient
100 contact. Secondary objectives were to compare seroprevalence rates between employees
101 working at different COVID-19 risk areas according to working place and to provide insight
102 into the effectiveness of and compliance with the use of PPE.

103

104 **Methods**

105 **Study design and setting**

106 The Co-HCW study (SARS-CoV-2 seroprevalence and infection status in employees at JUH)
107 is a prospective, single centre observational cohort study conducted at JUH, a 1,400-bed
108 academic hospital in Germany. Since 16th March 2020, 50 SARS-CoV-2 positive patients

109 were hospitalized and additional 73 SARS-CoV-2 positive outpatients were seen at the
110 emergency department (valid at 8th June 2020). Due to the increasing number of SARS-CoV-
111 2 cases (in Jena and at JUH), mandatory masking for all employees at JUH was implemented
112 on 20th March 2020. Research was conducted in accordance with the declaration of Helsinki
113 and national and institutional standards. The study protocol was approved by the local ethics
114 committee of the Friedrich-Schiller-University Jena (approval no. 2020-1774) and the study
115 was registered at the German Clinical Trials Register (DRKS00022432).

116

117 **Enrolment and data management**

118 Participants were recruited between 19th May 2020 and 19th June 2020. All employees of JUH
119 working at predefined areas with (HCWs) and without patient contact (administration
120 employees) (as provided in **Supplementary Table 1**) were eligible for inclusion. Eligible staff
121 members received information on the planned study per e-mail and/or were directly informed
122 per an on-site visit. Participation was voluntary. Employees were included if they signed a
123 written informed consent form, answered a questionnaire (see below) and agreed on
124 providing a blood sample (not exceeding 9 ml of venous blood).

125 Individuals working outside the precategorized risk areas (namely lab personal where at least
126 a proportion deals with COVID-19 related clinical specimens but has no patient contact) or
127 participating outside the planned study period were excluded.

128 After pseudonymization at the study center, blood samples were sent to the Department of
129 Clinical Chemistry and Laboratory Medicine (JUH) and the Institute of Medical Microbiology
130 (JUH) for testing of IgG antibodies against SARS-CoV-2 by two different immunoassays (see
131 below).

132 Pseudonymized questionnaires were digitalized with support of data management of the
133 Institute of General Practice and Family Medicine (JUH). After digitalization, the whole data
134 set was checked for plausibility and obvious errors were corrected.

135

136 **Questionnaire**

137 The questionnaire included questions on demographics, working area, individual exposure to
138 confirmed COVID-19 cases, return from COVID-19 risk areas since February 2020, results of
139 previous polymerase chain reaction (PCR) or serology test for COVID-19, clinical symptoms
140 within the last two months such as cold-like symptoms, diarrhea, taste disturbances and smell
141 disorders. The severity of respiratory symptoms, included in the Wisconsin Upper Respiratory
142 Symptom Survey (WURSS-24), was asked. WURSS-24 is identical to the WURSS-21 [22],
143 except for the addition of the items assessing headache, body ache and fever.

144 To evaluate the risk for nosocomial transmissions, HCWs with an individual face-to-face
145 contact within 1 meter with a confirmed COVID-19 patient or at least with its surroundings
146 received an extended questionnaire that also included questions on the compliance
147 concerning use of personal protective equipment (PPE) as recently published by the WHO

148 (<https://www.who.int/publications/i/item/risk-assessment-and-management-of-exposure-of->
149 [health-care-workers-in-the-context-of-covid-19-interim-guidance](https://www.who.int/publications/i/item/risk-assessment-and-management-of-exposure-of-health-care-workers-in-the-context-of-covid-19-interim-guidance)).

150

151 **SARS-CoV-2 antibody testing**

152 Presence of SARS CoV-2 antibodies was investigated by two different commercially available
153 IgG detecting immunoassays: an enzyme-linked immunosorbent assay EDI Novel
154 Coronavirus SARS-CoV-2 IgG ELISA (Epitope Diagnostics Inc., San Diego, USA) and a
155 chemiluminescence-based immunoassay Elecsys Anti-SARS-CoV-2 (Roche, Basel,
156 Switzerland). Both assays target recombinant nucleocapsid protein and were carried out
157 according to the manufacturers' instructions. Sensitivities and specificities as provided by the
158 manufacturers are high for both tests ($\geq 98\%$). In case of two corresponding negative test
159 results by both immunoassays, the participant was regarded as SARS-CoV-2 seronegative.
160 Volunteers with at least one positive test result were regarded as SARS-CoV-2 seropositive.
161 In case of a "borderline" test result for EDI IgG ELISA and a negative Elecsys Roche test, the
162 test persons was neither classified as SARS-CoV-2 seropositive nor seronegative.
163 Re-testing was offered to all participants with a divergent result of both immunoassays.

164

165 **Outcomes and further definitions**

166 The primary outcome of the study was to assess the seroprevalence of SARS-CoV-2
167 antibodies in employees using two IgG detecting immunoassays. Secondary outcomes were
168 (i) seroprevalence rates stratified by their risk of COVID-19 exposure during work (see below
169 for definition of COVID-19 risk areas), (ii) potential risk factors and clinical symptoms for
170 seropositive employees and (iii) compliance of HCWs in high-risk and intermediate-risk areas
171 to wear PPE in case of an individual reported contact with a confirmed COVID-19 positive
172 patient or its surroundings.

173 We classified employees in three groups according to their risk of a contact with COVID-19
174 patients: low, intermediate and high risk. The low-risk group included employees working in
175 the administration without patient contact. The intermediate-risk group had regular patient
176 contact but did not routinely treat patients with confirmed or suspected SARS-CoV-2
177 infections. The high-risk group included HCWs working at areas with confirmed COVID-19
178 patients and areas that deal with a high number of suspected COVID-19 cases (see
179 **Supplementary Table 1**).

180

181 **Sample size considerations**

182 As previous data on SARS CoV-2 IgG seroprevalence rates of HCWs in Germany were
183 sparse [23], our intention was to conduct an exploratory study focussing on the precision of
184 the prevalence estimate in the defined exposure groups (i.e. the group comparisons by
185 hypothesis test was not the primary objective). Thus, we assumed a true prevalence of 5%.
186 150 employees per group should be targeted to get 95% confidence intervals (for the
187 proportion) with a precision (half width of confidence interval) of about 3.5%.

188 **Statistical analysis**

189 Characteristics of participants are summarized (overall, stratified by test result) as absolute
190 and relative frequencies or as median together with first and third quartile (Q1, Q3).
191 Seroprevalence of SARS-CoV-2 in employees are described with absolute and relative
192 frequencies together with 95% Clopper-Pearson confidence intervals (CIs). To compare
193 seroprevalence rates between participants working at different COVID-19 risk areas, to
194 analyze clinical symptoms and to identify potential risk factors for seropositive compared to
195 seronegative participants, we apply univariable logistic regression modelling with the
196 seropositivity as dependent variable and the investigated factor as independent variable. We
197 provide odds ratios (OR) together with 95% CI. Compliance of HCWs (in high and
198 intermediate-risk areas) to wear PPE is assessed with Fisher exact test. We compare those
199 HCWs who stated to always or mostly wear PPE to those who stated not to wear PPE or did
200 not provide information on this issue.
201 We applied a two-sided significance level of 0.05 and did not correct for multiple testing as all
202 analyses were considered exploratory. Clopper-Pearson CIs were calculated with Microsoft
203 Excel 2016. All other analyses were done with SPSS Statistics version 25.0 for Windows
204 (IBM Corp., Armonk, NY, USA).

205 **Results**

206 **Characteristics of the study population**

207 We identified 3,228 employees who were eligible for study inclusion. Among them, 721
208 participants (22.3%) were included, and 660 of 721 participants (91.5%) could be analysed
209 (see Figure 1). Of the 660 analysed participants, 174 (26.4%) were males and 486 (73.6%)
210 were females. The median age of the participants was 40.5 (Q1-Q3: 32.0-49.0) years. The
211 most common professions involved included nurses (n=215, 32.6%), followed by
212 administration staff (n=180, 27.3%) and medical doctors (n=103, 15.6%), nursing assistants
213 (n=18; 2.7%), psychologists (n=18; 2.7%) and ergo therapists (n=17; 2.6%). Two-hundred six
214 employees (31.2%) reported direct exposure to a confirmed COVID-19 case. Among 198
215 employees with direct COVID-19 contact at work, 12 participants (6.1%) reported contact to a
216 SARS-CoV-2 positive colleague. Direct COVID-19 contact outside the JUH included
217 household contacts (n=4), patient contacts at other health care facilities (n=6), in the
218 ambulance (n=5) or at a home visit (n=1), direct contact in town (n=2), at vacation (n=1) or
219 with a former employee (n=1). Further details on the participants are provided in **Table 1**.

220

221 **Seroprevalence, infection status and previous testing for COVID-19**

222 Among the 660 participants, 627 (95.0%) were tested negative for SARS-CoV-2 IgG
223 antibodies by both immunoassays. Two participants (0.3%) were tested positive by Elecsys
224 Roche and EDI IgG ELISA and 16 participants (2.4%) were only tested positive by EDI IgG
225 ELISA. Fifteen participants had a “borderline” result for EDI IgG ELISA. Hence, 18 employees
226 (2.7%, 95% CI 1.6%-4.3%), 12 HCWs (2.5% within the group HCWs, 95% CI 1.3%-4.3%) and
227 6 administration employees (3.3% within the group administration employees, 95% CI 1.2%-
228 7.1%) had detectable SARS-CoV-2 IgG antibodies in at least one immunoassay. When
229 considering also previously reported PCR and serology results, cumulative SARS-CoV-2
230 infection rate in our participants was 3.2% (95% CI 2.0%-4.8%).

231 Among the 18 employees with detectable SARS-CoV-2 IgG antibodies, only 9 (50.0%)
232 reported clinical symptoms within the last two months (see **Table 2**).

233

234 **Follow-up of discrepant immunoassay results**

235 Thirteen of 15 participants (86.7%) with a “borderline” test result for EDI IgG ELISA and 12 of
236 16 participants (75.0%) with a positive result for EDI IgG ELISA but negative Elecsys Roche
237 test were retested after 1-2 months. All employees with a previous “borderline” test result for
238 EDI IgG ELISA became negative in the retest. For clinical symptoms in this group, we refer to
239 **Supplementary Table 2**. Three of 12 employees (25.0%) with a previous positive test result
240 for EDI IgG ELISA but negative Elecsys Roche test had unchanged test results 1-2 months
241 later, whereas 9 of 12 employees (75.0%) became negative in the retest. All 3 participants (2
242 HCWs and 1 administration employee) with a persistent positive test result for EDI IgG ELISA
243 but negative Elecsys Roche test did not report any clinical symptoms.

244 **Potential risk factors and clinical symptoms for antibody positivity of employees**

245 As shown in **Table 1**, we did not observe evidence for an association of antibody positivity
246 with the demographics, the professions or COVID-19 risk area (all p-values from logistic
247 regression >0.05). The two persons who were tested positive by both immunoassays were
248 administration employees. The only parameters that were associated with SARS-CoV-2
249 seropositivity in employees included close COVID-19 contact at home (OR 39.06, 95% CI
250 5.17 to 295.00), taste disturbances (OR 12.94, 95% CI 2.42 to 69.10) and smell disorders
251 (OR 5.90, 95% CI 1.23 to 28.36).

252

253 **Compliance to wear PPE in case of a individual contact with a COVID-19 positive**
254 **patient and/or its surroundings**

255 Reported compliance to wear PPE was associated with the COVID-19 risk area according to
256 the working place ($p < 0.001$). Compliance of HCWs working in COVID-19 high-risk was 98.3%
257 (yes: $n=114$; no: $n=2$) and in intermediate-risk areas 69.8% (yes: $n=62$, most time: $n=5$, no:
258 $n=21$, no answer given: $n=8$). Detailed information on compliance to wear different items of
259 PPE and different circumstances is given in **Figure 2**.

260 A single HCW reported a puncture/sharp accident with material contaminated with biological
261 fluid/respiratory secretions during a healthcare interaction with a COVID-19 patient. This
262 HCW remained seronegative.

263 Discussion

264 Altogether, seroprevalence of SARS-CoV-2 IgG was low in the investigated group (2.7%).
265 Even when we also considered reported previous PCR and serology results, the cumulative
266 SARS-CoV-2 infection rate remained below the expected 5% derived from reports of a similar
267 University hospital in Münster, Germany [23]. Higher seroprevalence rates among frontline
268 healthcare personnel were reported by recent studies outside Germany (ranging from 4.0% to
269 9.0%) [24-26].

270 Among 660 tested employees of JUH, we did not detect an association between
271 seroprevalence and risk area according to their workplace. Contrary, HCWs working at
272 COVID-19 high-risk areas had the numerically lowest (1.5%) and employees without any
273 patient contact had the numerically highest seroprevalence rates (3.3%).

274 We found an association between seroprevalence rates and a reported individual exposure to
275 a SARS-CoV-2 positive household contact. Similarly, Luo *et al.* who evaluated the risk for
276 transmission in 3,410 close contacts of COVID-19 patients identified household contact as
277 the main setting for transmission of SARS-CoV-2 (10.3%) [27]. Community acquisition is
278 hence a major aspect that needs to be considered.

279 In the present study, HCWs in the high-risk group reported a remarkable compliance of
280 98.2% regarding PPE administration whereas compliance in the intermediate-risk group was
281 significantly lower with 69.8%. Consequent use of PPE is an effective measure to minimise
282 the risk of infection [20, 24]. We assume that the awareness regarding personal protection
283 was higher in those HCWs who are repeatedly exposed to COVID-19 patients. An increased
284 awareness might lead to better adherence to other hygienic measurements as well [28]. In
285 addition, a daily routine in PPE use improves correct donning and doffing and thus, reduces
286 the risk of contamination. The results of the study support the importance of adequate PPE
287 use to prevent transmission from patient to HCW. Additionally, mandatory masking might
288 have reduced nosocomial transmissions also in employees without patient contact. However,
289 compliance to mandatory masking during working hours was not evaluated in our study.
290 According to Wang *et al.*, implementation of mandatory masking of HCWs and patients can
291 be effective to reduce SARS-CoV-2 infection rates [29]. In a recently published report by Self
292 *et al.* that included 3,248 frontline HCWs, seroprevalence of SARS-CoV-2 antibodies was
293 lower among HCWs who reported always wearing a face covering while caring for patients
294 compared to those who did not (6% versus 9%) [24].

295 It is known, that pre- and asymptomatic COVID-19 infected persons can be contagious
296 despite absence of any subjective feeling of illness. In a population-based study by
297 Gudbjartsson *et al.* including 30,576 people from Iceland, nearly one third of the SARS-CoV-2
298 infections were asymptomatic and durability of SARS-CoV-2 antibody levels was over 4
299 months [30]. In our study population, only 50% of those tested positive reported any clinical
300 symptoms, but the presence of taste disturbances or smell disorders were both associated
301 with seropositivity of SARS-CoV-2 IgG. Similarly, the authors Iversen *et al.* identified loss of

302 smell or taste as the symptom that was most strongly associated with seropositivity in HCWs
303 in Denmark [26]. In a complete cohort study following up a COVID-19 outbreak in a German
304 village, we found that loss of taste and smell were the symptoms exhibiting the highest
305 association with PCR positivity [21].

306 The validity regarding sensitivity and specificity of SARS-CoV-2 serology testing has not yet
307 been investigated entirely [31]. According to the recently published IDSA guidelines on the
308 diagnosis of COVID-19 there will be false positive and false negative tests, but the most
309 reliable spot of measuring SARS-CoV-2 antibodies is 3-4 weeks after exposure to the
310 virus/onset of clinical symptoms [32]. In the present study we used two different
311 immunoassays, the Elecsys Anti-SARS CoV-2 Roche Diagnostics and the EDI Novel
312 Coronavirus SARS-CoV-2 IgG ELISA. A recent head-to-head comparison of both
313 immunoassays found acceptable agreement between both tests [33]. In our study the Roche
314 Elecsys assay did not identify asymptomatic COVID-19 cases, which was already observed in
315 the CoNAN study mentioned above [21]. This assay was only positive in 2 participants (0.3%)
316 who were tested at beginning of June 2020 and had developed a symptomatic COVID-19
317 disease in the second half of March 2020. In contrast, the EDI IgG ELISA was positive in
318 2.7% of participants (9 asymptomatic and 9 symptomatic cases) including the two persons
319 with the positive Roche Elecsys assay. It is still a matter of debate to what extend
320 seroprevalence of SARS-CoV-2 IgG can really reflect immunity and status after infection.
321 Nonetheless, serological examination is a method which is easily available and highly cost-
322 effective compared to PCR [34].

323 This study has the following limitations: Despite the high number of participants, the
324 recruitment rate was below 10% of the total JUH staff and results of previous COVID-19
325 testing and compliance using PPE were only recorded by self-reports. We determined
326 antibody titres repeatedly only in those with discrepant results. As SARS-CoV-2 infection
327 generates two waves of antibodies, the provided data do not reflect long-lived immunity [34].

328

329 **Conclusion**

330 In our study, reported contact with a COVID-19 patient was not found to be a risk factor for
331 seroprevalence of SARS CoV-2 antibodies, whereas contacts with infected family members
332 was highly predictive. In line, we found a high awareness and compliance with PPE and no
333 evidence for higher seroprevalence in HCWs caring for COVID-19 patients, whereas
334 administration employees with no patient contacts had numerically higher seroprevalence
335 rates. We conclude that for HCWs, community transmission may play a larger role for
336 COVID-19 infection than professional exposure when using appropriate PPE.

337

338 **Acknowledgements**

339 We thank Stefanie Baier, Jana Schmidt, Stefanie Kolanos and Monique Philippe for excellent
340 technical support.

341 **Author contributions**

342 CB, AK, MWP had full access to all of the data in the study and take responsibility for the
343 integrity of the data and the accuracy of the data analysis.

344 Study concept and design: SW, MWP, ASch, JM, BL, MKi, ASta, ASte, MBau, WB, FZ, MW.

345 Acquisition of data: CB, AK, SH, JA.

346 Performing of seroprevalence testing: CR, MKi, MBai, BL.

347 Statistical analyses: CB, MKe.

348 Drafting of the manuscript: CB, AK, MKe, MWP.

349 Critical revision of the manuscript and additional important intellectual content, data
350 interpretation: all authors.

351 Study supervision: MWP, CB.

352 **Conflict of interest statement**

353 None to declare.

354

355 **Funding**

356 This study financed by internal funding.

357 References

358

359 [1] Huang C, Wang Y, Li X, *et al.* **Clinical features of patients infected with 2019**
360 **novel coronavirus in Wuhan, China.** *Lancet* 2020; 395(10223): 497-506. doi:
361 10.1016/S0140-6736(20)30183-5.

362 [2] Ralph R, Lew J, Zeng T, *et al.* **2019-nCoV (Wuhan virus), a novel Coronavirus:**
363 **human-to-human transmission, travel-related cases, and vaccine readiness.** *J*
364 *Infect Dev Ctries* 2020; 14(1): 3-17. doi: 10.3855/jidc.12425.

365 [3] Whitworth J. **COVID-19: a fast evolving pandemic.** *Trans R Soc Trop Med Hyg*
366 2020; 114(4): 241-8. doi: 10.1093/trstmh/traa025.

367 [4] Abebe EC, Dejenie TA, Shiferaw MY, Malik T. **The newly emerged COVID-19**
368 **disease: a systemic review.** *Virol J* 2020; 17(1): 96. doi: 10.1186/s12985-020-
369 01363-5.

370 [5] Chen N, Zhou M, Dong X, *et al.* **Epidemiological and clinical characteristics of 99**
371 **cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive**
372 **study.** *Lancet* 2020; 395(10223): 507-13. doi: 10.1016/S0140-6736(20)30211-7.

373 [6] Guan WJ, Ni ZY, Hu Y, *et al.* **Clinical Characteristics of Coronavirus Disease**
374 **2019 in China.** *N Engl J Med* 2020; 382(18): 1708-20. doi:
375 10.1056/NEJMoa2002032.

376 [7] Pergolizzi JV, Jr., Magnusson P, LeQuang JA, *et al.* **The Current Clinically**
377 **Relevant Findings on COVID-19 Pandemic.** *Anesth Pain Med* 2020; 10(2):
378 e103819. doi: 10.5812/aapm.103819.

379 [8] Long QX, Tang XJ, Shi QL, *et al.* **Clinical and immunological assessment of**
380 **asymptomatic SARS-CoV-2 infections.** *Nat Med* 2020; 26(8): 1200-4. doi:
381 10.1038/s41591-020-0965-6.

382 [9] Furukawa NW, Brooks JT, Sobel J. **Evidence Supporting Transmission of Severe**
383 **Acute Respiratory Syndrome Coronavirus 2 While Presymptomatic or**
384 **Asymptomatic.** *Emerg Infect Dis* 2020; 26(7). doi: 10.3201/eid2607.201595.

385 [10] He X, Lau EHY, Wu P, *et al.* **Temporal dynamics in viral shedding and**
386 **transmissibility of COVID-19.** *Nat Med* 2020; 26(5): 672-5. doi: 10.1038/s41591-
387 020-0869-5.

388 [11] Slifka MK, Gao L. **Is presymptomatic spread a major contributor to COVID-19**
389 **transmission?** *Nat Med* 2020 Aug 17. doi: 10.1038/s41591-020-1046-6.

390 [12] Fischer-Fels J. **Gesundheitspersonal und COVID-19: Infektionszahlen nehmen**
391 **zu.** *Dtsch Arztebl* 2020; 117(31-32): A-1484/B-1275.
392 [https://www.aerzteblatt.de/archiv/214843/Gesundheitspersonal-und-COVID-19-](https://www.aerzteblatt.de/archiv/214843/Gesundheitspersonal-und-COVID-19-Infektionszahlen-nehmen-zu)
393 [Infektionszahlen-nehmen-zu.](https://www.aerzteblatt.de/archiv/214843/Gesundheitspersonal-und-COVID-19-Infektionszahlen-nehmen-zu)

394 [13] Patel KP, Vunnam SR, Patel PA, *et al.* **Transmission of SARS-CoV-2: an update of**
395 **current literature.** *Eur J Clin Microbiol Infect Dis* 2020; 1-7.
396 doi: 10.1007/s10096-020-03961-1.

- 397 [14] Reychler G, Vecellio L, Dubus JC, *et al.* Nebulization: **A potential source of SARS-**
398 **CoV-2 transmission.** *Respir Med Res* 2020; 78: 100778. doi:
399 10.1016/j.resmer.2020.100778.
- 400 [15] Taylor J, Rangaiah J, Narasimhan S, *et al.* **Nosocomial Coronavirus Disease 2019**
401 **(COVID-19): Experience from a large Acute NHS Trust in South-West London.** *J*
402 *Hosp Infect* 2020 Aug 22:S0195-6701(20)30405-9. doi: 10.1016/j.jhin.2020.08.018.
- 403 [16] Baker MA, Rhee C, Fiumara K, *et al.* **COVID-19 infections among HCWs exposed**
404 **to a patient with a delayed diagnosis of COVID-19.** *Infect Control Hosp Epidemiol*
405 2020 May 27:1-2. doi: 10.1017/ice.2020.256.
- 406 [17] Zhao D, Wang M, Wang M, *et al.* **Asymptomatic infection by SARS-CoV-2 in**
407 **healthcare workers: A study in a large teaching hospital in Wuhan, China.** *Int J*
408 *Infect Dis* 2020; 99: 219-25. doi: 10.1016/j.ijid.2020.07.082.
- 409 [18] Treibel TA, Manisty C, Burton M, *et al.* **COVID-19: PCR screening of asymptomatic**
410 **health-care workers at London hospital.** *Lancet* 2020; 395(10237): 1608-10. doi:
411 10.1016/S0140-6736(20)31100-4.
- 412 [19] **A blind spot in the Covid-19 epidemic: Nosocomial transmission to healthcare**
413 **workers.** *Bull Acad Natl Med* 2020. doi: 10.1016/j.banm.2020.05.056.
- 414 [20] Chou R, Dana T, Buckley DI, Selph S, Fu R, Totten AM. **Epidemiology of and Risk**
415 **Factors for Coronavirus Infection in Health Care Workers: A Living Rapid**
416 **Review.** *Ann Intern Med* 2020; 173(2): 120-36. doi: 10.7326/M20-1632.
- 417 [Preprint] [21] Weis S, Scherag A, Baier M, *et al.* **Seroprevalence of SARS-CoV-2**
418 **antibodies in an entirely PCR-sampled and quarantined community after a**
419 **COVID-19 outbreak - the CoNAN study.** *medRxiv* 2020. doi:
420 <https://doi.org/10.1101/2020.07.15.20154112>
- 421 [22] Barrett B, Brown R, Mundt M, *et al.* **The Wisconsin Upper Respiratory Symptom**
422 **Survey is responsive, reliable, and valid.** *J Clin Epidemiol* 2005; 58(6): 609-17.
423 doi: 10.1016/j.jclinepi.2004.11.019.
- 424 [23] Schwierzeck V, Correa-Martinez CL, Schneider KN, *et al.* **SARS-CoV-2 in the**
425 **Employees of a Large University Hospital.** *Dtsch Arztebl Int* 2020; 117(19): 344-5.
426 doi: 10.3238/arztebl.2020.0344 .
- 427 [24] Self WH, Tenforde MW, Stubblefield WB, *et al.* **Seroprevalence of SARS-CoV-2**
428 **Among Frontline Health Care Personnel in a Multistate Hospital Network - 13**
429 **Academic Medical Centers, April-June 2020.** *MMWR Morb Mortal Wkly Rep*
430 2020;69:1221-6. doi: 10.15585/mmwr.mm6935e2.
- 431 [25] Garcia-Basteiro AL, Moncunill G, Tortajada M, *et al.* **Seroprevalence of antibodies**
432 **against SARS-CoV-2 among health care workers in a large Spanish reference**
433 **hospital.** *Nat Commun* 2020; 11(1): 3500. doi: 10.1038/s41467-020-17318-x.
- 434 [26] Iversen K, Bundgaard H, Hasselbalch RB, *et al.* **Risk of COVID-19 in health-care**
435 **workers in Denmark: an observational cohort study.** *Lancet Infect Dis* 2020 Aug
436 3;S1473-3099(20)30589-2. doi: 10.1016/S1473-3099(20)30589-2.

- 437 [27] Luo L, Liu D, Liao X, *et al.* **Contact Settings and Risk for Transmission in 3410**
438 **Close Contacts of Patients With COVID-19 in Guangzhou, China : A Prospective**
439 **Cohort Study.** *Ann Intern Med* 2020 Aug 13;M20-2671.
440 doi: 10.7326/M20-2671.
- 441 [28] Houghton C, Meskell P, Delaney H, *et al.* **Barriers and facilitators to healthcare**
442 **workers' adherence with infection prevention and control (IPC) guidelines for**
443 **respiratory infectious diseases: a rapid qualitative evidence synthesis.**
444 *Cochrane Database Syst Rev* 2020; 4: CD013582. doi:
445 10.1002/14651858.CD013582.
- 446 [29] Wang X, Ferro EG, Zhou G, Hashimoto D, Bhatt DL. **Association Between**
447 **Universal Masking in a Health Care System and SARS-CoV-2 Positivity Among**
448 **Health Care Workers.** *JAMA* 2020. 324(7):703-704. doi: 10.1001/jama.2020.12897.
- 449 [30] Gudbjartsson DF, Norddahl GL, Melsted P, *et al.* **Humoral Immune Response to**
450 **SARS-CoV-2 in Iceland.** *N Engl J Med* 2020 Sep 1. doi: 10.1056/NEJMoa2026116.
- 451 [31] Deeks JJ, Dinnes J, Takwoingi Y, *et al.* **Antibody tests for identification of current**
452 **and past infection with SARS-CoV-2.** *Cochrane Database Syst Rev* 2020; 6:
453 CD013652. doi: 10.1002/14651858.CD013652.
- 454 [32] Hanson KE, Caliendo AM, Arias CA, *et al.* **Infectious Diseases Society of America**
455 **Guidelines on the Diagnosis of COVID-19:Serologic Testing.** *Clin Infect Dis.* 2020
456 Sep 12:ciaa1343. doi: 10.1093/cid/ciaa1343.
- 457 [33] Egger M, Bundschuh C, Wiesinger K, *et al.* **Comparison of the Elecsys(R) Anti-**
458 **SARS-CoV-2 immunoassay with the EDI enzyme linked immunosorbent assays**
459 **for the detection of SARS-CoV-2 antibodies in human plasma.** *Clin Chim Acta*
460 2020; 509: 18-21. doi: 10.1016/j.cca.2020.05.049.
- 461 [34] Alter G, Seder R. **The Power of Antibody-Based Surveillance.** *N Engl J Med* 2020
462 Sep 1. doi: 10.1056/NEJMe20280

Table 1. Characteristics of the study population – overall and stratified by antibody test result (SARS CoV-2 IgG)

Variable	Overall (n = 660)	SARS CoV-2 IgG		Logistic regression	
		Detectable (n = 18)	Not detectable (n = 627)	OR (95% CI)	p-value
<i>Demographics</i>					
Age, in years	40.5 (32.0, 49.0)	43.0 (35.3, 52.3)	40.0 (32.0, 49.0)	1.02 (0.98, 1.07)	0.310
Male sex	174 (26.4%)	5 (27.8%)	169 (27.0%)	1.04 (0.37, 2.97)	0.938
<i>Profession^a</i>					
Medical doctor	103 (15.6%)	5 (27.8%)	94 (15.0%)	ref.	0.413
Nurse or care worker	215 (32.6%)	5 (27.8%)	206 (32.9%)	0.46 (0.13, 1.61)	0.224
Cleaner	6 (0.9%)	1 (5.6%)	5 (0.8%)	3.76 (0.37, 38.56)	0.265
Reception staff	19 (2.9%)	1 (5.6%)	18 (2.9%)	1.04 (0.12, 9.48)	0.969
Administration staff	180 (27.3%)	6 (33.3%)	169 (27.0%)	0.67 (0.20, 2.25)	0.514
Other profession	130 (19.7%)	0 (0.0%)	128 (20.4%)	-	-
<i>COVID-19 risk group according to working place</i>					
High-risk	137 (20.8%)	2 (11.1%)	133 (21.2%)	ref.	0.574
Intermediate-risk	343 (52.0%)	10 (55.6%)	325 (51.8%)	2.05 (0.44, 9.46)	0.360
Low-risk	180 (27.3%)	6 (33.3%)	169 (27.0%)	2.36 (0.47, 11.89)	0.298
<i>Returning from risk areas since February 2020</i>					
Yes	85 (12.9%)	1 (5.6%)	83 (13.2%)	0.39 (0.05, 2.93)	0.357
<i>Reported COVID-19 exposure</i>					
Reported exposure	206 (31.2%)	5 (27.8%)	199 (31.7%)	0.83 (0.29, 2.35)	0.722
<i>Place of reported exposure^{b,c}</i>					
At work	198 (30.0%)	3 (16.7%)	193 (30.8%)	0.45 (0.13, 1.57)	0.211
At home	4 (0.6%)	2 (11.1%)	2 (0.3%)	39.06 (5.17, 295.00)	<0.001
Other place	16 (2.4%)	0 (0.0%)	16 (8.0%)	-	-
<i>Clinical symptoms within the last two months^d</i>					
Any clinical symptom	272 (41.2%)	9 (50.0%)	254 (40.5%)	1.47 (0.58, 3.75)	0.422
Cold-like symptoms	249 (37.7%)	9 (50.0%)	232 (37.0%)	1.70 (0.67, 4.35)	0.266
Diarrhea	72 (10.9%)	2 (11.1%)	68 (10.8%)	1.03 (0.23, 4.57)	0.971
Taste disturbance	9 (1.4%)	2 (11.1%)	6 (1.0%)	12.94 (2.42, 69.10)	0.003
Smell disorders	16 (2.4%)	2 (11.1%)	13 (2.1%)	5.90 (1.23, 28.36)	0.027

The number of participants (n) is provided. Median together with first and third quartile or absolute and relative frequencies are provided. Furthermore, results from univariable logistic regression modelling (odds ratio (OR) with 95% confidence interval (CI) and p-value) comparing staff members with detectable SARS CoV-2 IgG antibodies by at least one immunoassay and HCWs without detectable SARS CoV-2 by both immunoassays are given. The reference category (ref.) is provided, if

necessary. HCWs with a borderline test result by EDI ELISA IgG and a negative Elecsys Roche test (n=15) are included in the overall characterization but were neither classified as seronegative nor as seropositive. For detailed results of this subgroup see **Supplementary Table 2**. Abbreviations: -, not applicable.

^a Information on profession is missing for 7 participants. "other profession" excluded from logistic regression analysis due to sample size issues in the two groups.

^b multiple answers possible.

^c "other place" excluded from logistic regression analysis due to sample size issues in the two groups.


Table 2. Current and reported test results and clinical symptoms for COVID-19 in employees of Jena University Hospital stratified by (a) detectable antibodies after recruitment, (b) history of past positive SARS-CoV-2 polymerase chain reaction (PCR) or serology, and (c) any evidence of a COVID-19 infection

	Employees seropositive for SARS-CoV-2 IgG antibodies after recruitment	Employees with reported evidence of a positive SARS-CoV-2 test prior recruitment	Employees with any evidence of past/current SARS-CoV-2 infection
<i>Overall</i>			
Number of Employees	18 out of 660 tested	4 out of 212 tested	21 out of 660 tested
Proportion (95% CI)	2.7% (1.6% to 4.3%)	1.9% (0.5% to 4.8%)	3.2% (2.0% to 4.8%)
<i>Among respective Employees</i>			
Not previously diagnosed as COVID-19 by PCR or serology	17 (94.4%, 72.7% to 99.9%)	-	17 (81.0%, 58.1% to 94.6%)
COVID-19 symptoms reported	9 (50.0%, 26.0% to 74.0%)	4 (100%, 38.8% to 100.0%)	12 (57.1%, 34.0% to 78.2%)
Maximum severity of cold-like symptoms within the last two months	0.5 (0.0, 4.0)	3.0 (1.3, 4.0)	1.0 (0.0, 4.0)


Absolute and relative frequencies together with 95% Clopper-Pearson confidence intervals (CI) or median together with first and third quartile are reported. Severity of illness (cold-like symptoms) is defined according to the Wisconsin Upper Respiratory Symptom Survey (0=no illness, 1-2=very mild, 3-4=mild, 5-6=moderate, 7=severe). Abbreviations: -, not applicable.

Figure 1: Flow chart of the Co-HCW study. The number of employees (n) are provided. Reasons for exclusions are given. Employees working at predefined areas at Jena University Hospital (JUH) were eligible for study inclusion. Working areas were classified into three categories according to the risk to deal with COVID-19 positive patients (see Supplementary Table 1 for the definition). Note that we decided not to assign lab personal to a pre-categorized risk area because a proportion dealt with COVID-19 related clinical specimens but there was no patient contact.

Figure 2. Compliance to wear personal protective equipment (PPE) in case of an individual reported contact with a confirmed COVID-19 positive patient or its surroundings in healthcare workers (HCWs) from (a) high-risk COVID-19 areas (n=116 HCWs) versus (b) intermediate-risk COVID-19 areas (n=96 HCWs). The definitions of risk areas are provided in **Supplementary Table 1**.



a



medRxiv preprint doi: <https://doi.org/10.1101/2020.09.29.20203737>; this version posted September 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

b

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

